BioSpace News Archive

CareDx, Inc. announced it will be hosting two symposia to share the latest data on CareDx products at the 2021 European Federation for Immunogenetics and Histocompatibility Conference, together with the British Society for Histocompatibility and Immunogenetics, which will take place between April 21-23, 2021.

Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021

Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director

Leading BioSciences, Inc., a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc., subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it has received innovative licensing and access pathway designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma.

Pharmactive Biotech, S.L., is tapping into the pharmaceutical market with its leading branded ingredients, such as affron® saffron extract, for supporting mental health.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis from the European Medicines Agency Committee for Orphan Medicinal Products.

Gala Therapeutics, Inari Medical, and Lumicell modernize research operations to manage growing complexity in trials and improve compliance

Innovative therapy targeting the root cause of the disease has received orphan drug designation by the U.S. FDA and European Medicines Agency